Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination

Journal of Immunology

Volumn 186, Issue 9, 2011, Pages 5107-5118

  Chen, Antony ^a   Ahlén, Gustaf ^a   Brenndörfer, Erwin D ^a   Brass, Anette ^a   Holmström, Fredrik ^a   Chen, Margaret ^b   Söderholm, Jonas ^c   Milich, David R ^d   Frelin, Lars ^a   Sällberg, Matti ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d Vaccine Research Institute of San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEPATITIS B CORE ANTIGEN; HEPATITIS C VACCINE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROGRAMMED DEATH 1 RECEPTOR; TOLL LIKE RECEPTOR 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG SPECIFICITY; EFFECTOR CELL; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS CORE; WILD TYPE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, VIRAL; BLOTTING, WESTERN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPACIVIRUS; HEPATITIS B CORE ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOPRECIPITATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES; VACCINATION; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 79955527858     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001790     Document Type: Article

References (36)

1. Gale, M., Jr., and E. M. Foy. 2005. Evasion of intracellular host defence by hepatitis C virus. Nature 436: 939-945.
2. Bowen, D. G., and C. M. Walker. 2005. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946-952.
3. + T-cell responsiveness in hepatitis C virus infection. Hepatology 33: 267-276.
4. + T-cell response in acute hepatitis C. Gastroenterology 117: 933-941.
5. Grakoui, A., N. H. Shoukry, D. J. Woollard, J. H. Han, H. L. Hanson, J. Ghrayeb, K. K. Murthy, C. M. Rice, and C. M. Walker. 2003. HCV persistence and immune evasion in the absence of memory T cell help. Science 302: 659-662.
6. + T lymphocytes after infection with hepatitis C virus. J. Virol. 75: 5550-5558.
7. Nascimbeni, M., E. Mizukoshi, M. Bosmann, M. E. Major, K. Mihalik, C. M. Rice, S. M. Feinstone, and B. Rehermann. 2003. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J. Virol. 77: 4781-4793. (Pubitemid 36402828)
8. + T cells in chronic hepatitis C virus infection. J. Immunol. 169: 3447-3458.
9. Cox, A. L., T. Mosbruger, Q. Mao, Z. Liu, X. H. Wang, H. C. Yang, J. Sidney, A. Sette, D. Pardoll, D. L. Thomas, and S. C. Ray. 2005. Cellular immune selection with hepatitis C virus persistence in humans. J. Exp. Med. 201: 1741-1752.
10. Erickson, A. L., Y. Kimura, S. Igarashi, J. Eichelberger, M. Houghton, J. Sidney, D. McKinney, A. Sette, A. L. Hughes, and C. M. Walker. 2001. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15: 883-895.
11. Söderholm, J., G. Ahlén, A. Kaul, L. Frelin, M. Alheim, C. Barnfield P. Liljeström, O. Weiland, D. R. Milich, R. Bartenschlager, and M. Sällberg. 2006. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut 55: 266-274. (Pubitemid 43117288)
12. Soderholm, J., and M. Sallberg. 2006. A complete mutational fitness map of the hepatitis C virus nonstructural 3 protease: relation to recognition by cytotoxic T lymphocytes. J. Infect. Dis. 194: 1724-1728.
13. Urbani, S., B. Amadei, D. Tola, M. Massari, S. Schivazappa, G. Missale, and C. Ferrari. 2006. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 80: 11398-11403. (Pubitemid 44706581)
14. Urbani, S., B. Amadei, D. Tola, G. Pedrazzi, L. Sacchelli, M. C. Cavallo, A. Orlandini, G. Missale, and C. Ferrari. 2008. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J. Hepatol. 48: 548-558.
15. + T cells during acute HCV infection, irrespective of clinical outcome. J. Virol. 82: 3154-3160.
16. Rollier, C. S., G. Paranhos-Baccala, E. J. Verschoor, B. E. Verstrepen J. A. Drexhage, Z. Fagrouch, J. L. Berland, F. Komurian-Pradel, B. Duverger, N. Himoudi, et al. 2007. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 45: 602-613. (Pubitemid 46450611)
17. Plotkin, S. A. 2003. Vaccines, vaccination, and vaccinology. J. Infect. Dis. 187:1349-1359.
18. Sallberg, M., H. Diepolder, M. C. Jung, L. Frelin, I. Mathiesen, M. Fons, R. W. Hultcrantz, T. Carlsson, and O. Weiland. 2008. Antiviral effects of therapeutic vaccination with naked DNA delivered by in vivo electroporation in patients with chronic hepatitis C. Hepatology 48: 1022A-1023A.
19. Cardell, K., B. Akerlind, M. Sällberg, and A. Frydén. 2008. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J. Infect. Dis. 198: 299-304.
20. Lee, B. O., A. Tucker, L. Frelin, M. Sallberg, J. Jones, C. Peters, J. Hughes, D. Whitacre, B. Darsow, D. L. Peterson, and D. R. Milich. 2009. Interaction of the hepatitis B core antigen and the innate immune system. J. Immunol. 182:6670-6681.
21. Nystrom, J., A. Chen, L. Frelin, G. Ahlen, S. Koh, A. Brass, D. L. Peterson, M. Fons, D. R. Milich, C. Hultgren, and M. Sallberg. 2010. Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes. J. Infect. Dis. 201: 1867-1879.
22. 2 microglobulin (β2m) HLA-A2.1 monochain transgenic H-2Db β2m double knockout mice. J. Exp. Med. 185: 2043-2051.
23. Frelin, L., E. D. Brenndörfer, G. Ahlén, M. Weiland, C. Hultgren, M. Alheim, H. Glaumann, B. Rozell, D. R. Milich, J. G. Bode, and M. Sällberg. 2006. The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor a mediated liver disease. Gut 55: 1475-1483. (Pubitemid 44476794)
24. Frelin, L., G. Ahlén, M. Alheim, O. Weiland, C. Barnfield, P. Liljeström, and M. Sällberg. 2004. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther. 11: 522-533. (Pubitemid 38443519)
25. Billaud, J. N., D. Peterson, M. Barr, A. Chen, M. Sallberg, F. Garduno, P. Goldstein, W. McDowell, J. Hughes, J. Jones, and D. Milich. 2005. Combinatorial approach to hepadnavirus-like particle vaccine design. J. Virol. 79:13656-13666. (Pubitemid 41508177)
26. Kuhöber, A., H. P. Pudollek, K. Reifenberg, F. V. Chisari, H. J. Schlicht, J. Reimann, and R. Schirmbeck. 1996. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J. Immunol. 156: 3687-3695. (Pubitemid 26137654)
27. Frelin, L., M. Alheim, A. Chen, J. Söderholm, B. Rozell, C. Barnfield, P. Liljeström, and M. Sällberg. 2003. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther. 10: 686-699. (Pubitemid 36553614)
28. Sällberg, M., U. Rudén, L. O. Magnius, E. Norrby, and B. Wahren. 1991. Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol. Lett. 30: 59-68.
29. + T cells. J. Immunol. 179: 4741-4753.
30. Ahlén, G., E. Derk, M. Weiland, J. Jiao, N. Rahbin, S. Aleman, D. L. Peterson, K. Pokrovskaja, D. Grandér, L. Frelin, and M. Sällberg. 2009. Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes. Gut 58: 560-569.
31. Frelin, L., T. Wahlström, A. E. Tucker, J. Jones, J. Hughes, B. O. Lee, J. N. Billaud, C. Peters, D. Whitacre, D. Peterson, and D. R. Milich. 2009. mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J. Virol. 83: 1379-1392.
32. Lazdina, U., M. Alheim, J. Nyström, C. Hultgren, G. Borisova, I. Sominskaya, P. Pumpens, D. L. Peterson, D. R. Milich, and M. Sällberg. 2003. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J. Gen. Virol. 84: 139-146.
33. Ljunggren, H. G., N. J. Stam, C. Ohlén, J. J. Neefjes, P. Höglund, M. T. Heemels, J. Bastin, T. N. Schumacher, A. Townsend, K. Kärre, et al. 1990. Empty MHC class I molecules come out in the cold. Nature 346: 476-480.
34. Ahlen, G., J. Nystrom, I. Pult, L. Frelin, C. Hultgren, and M. Sallberg. 2005. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J. Infect. Dis. 192: 2112-2116.
35. Billaud, J. N., D. Peterson, B. O. Lee, T. Maruyama, A. Chen, M. Sallberg, F. Garduño, P. Goldstein, J. Hughes, J. Jones, and D. Milich. 2007. Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. Vaccine 25:1593-1606. (Pubitemid 46108210)
36. Billaud, J. N., D. Peterson, F. Schödel, A. Chen, M. Sallberg, F. Garduno, P. Goldstein, W. McDowell, J. Hughes, J. Jones, and D. Milich. 2005. Comparative antigenicity and immunogenicity of hepadnavirus core proteins. J. Virol. 79: 13641-13655 (Pubitemid 41508176)